Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

阿尔茨海默病创新药物疗效 - 礼来多奈单抗注射液在三年长期扩展研究中显示持续减缓疾病进展 早期使用可将疾病进展至下一阶段风险降低27% [3] - 超过75%早期使用多奈单抗患者在76周内达到淀粉样蛋白清除 最长观察期2.5年显示大脑淀粉样斑块重新沉积速率缓慢（约2.4 CL/年） [3] - 卫材和Biogen的仑卡奈单抗治疗四年后持续减缓病情 认知能力下降速度减缓34% [5] 药物安全性数据 - 多奈单抗三年随访未出现新的安全性信号 但存在与淀粉样蛋白治疗相关的ARIA副作用（水肿/出血） ApoE4等位基因携带者风险更高 [4] - 仑卡奈单抗四年随访同样未出现新的安全问题 [5] - 药物相关脑肿胀和出血主要发生在治疗前六个月 [4] 中国市场应用现状 - 多奈单抗2025年3月刚进入中国临床 长期有效性尚未纳入中国患者数据 [4] - 仑卡奈单抗在中国临床使用已超一年 但长期随访数据同样缺乏中国患者样本 [4][5] - 中国阿尔茨海默病患者约983万 其中早期患者占比约20% 需经基因分型筛查才能确定适用创新药人群 [5] 治疗适用人群范围 - 创新药物仅适用于经生物标志物诊断的早期患者（轻度认知障碍期） 日常生活能力未受显著影响 [5]

Key Takeaways BIIB's Q2 EPS of $5.47 and revenues of $2.65B beat estimates, driven by new drugs.Vumerity, Leqembi, and Zurzuvae showed strong demand and sequential sales growth in the quarter.BIIB raised its 2025 EPS outlook to $15.50-$16.00 and now sees flat full-year revenue versus prior decline.Biogen (BIIB) reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks Consensus Estimate of $3.93. Earnings rose 4% year over year on a reported basis.Total reve ...

Biogen (BIIB) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Company ParticipantsTim Power - Head of IRChristopher Viehbacher - President, CEO & DirectorPriya Singhal - EVP & Head - DevelopmentAlisha Alaimo - President & Head - North AmericaRobin Kramer - EVP & CFOPhilip Nadeau - MD, Health Care – BiotechnologyMichael Yee - Managing DirectorUmer Raffat - Senior Managing DirectorBrian Abrahams - MD & Co-Head of Biotechnology ResearchSalveen Richter - Biotechnology Equity ResearchConference Call Participants ...

Biogen (BIIB) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter twenty twenty five Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer question remarks, Today's conference is being recorded. AndThank you. I would now like to turn the ...

July 31, 2025 SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE FORWARD-LOOKING STATEMENTS This presentation and the discussions during this conference call contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-19311 BIOGEN INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 33-0112644 (I.R.S. Employer Ide ...

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.94 per share in its upcoming release, pointing to a year-over-year decline of 25.4%. It is anticipated that revenues will amount to $2.32 billion, exhibiting a decrease of 5.8% compared to the year-ago quarter.Over the last 30 days, there has been a downward revision of 2.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of ...

阿尔茨海默药物市场前景 - 渤健-卫材的Leqembi和礼来的Kisunla预计将主导阿尔茨海默药物市场 但2030年市场规模预期从130亿美元大幅下调至60亿美元 [3] - 研发挫折、安全性风险及药物应用缓慢是市场预期下调的主要原因 风险调整后销售预期削减70亿美元 [3][8] - 到2030年 阿尔茨海默药物总销售预计达60亿美元 其中近10亿美元来自新机制药物 [5][16] 主要药物销售预测 - 2025年Leqembi与Kisunla合计销售或达5.91亿美元 2030年有望增长近七倍至40亿美元 较市场普遍预期低24% [4] - Leqembi的2025年销售预期为4.01亿美元 较市场普遍预期低16% 2030年渤健销售分成预计为9.48亿美元 [13] - Kisunla的2025年销售预测为1.79亿美元 较市场普遍预期高出42% 主要得益于剂量调整安全性提升 [4] 市场竞争格局 - 渤健-卫材预计在2028年前主导市场 但礼来有望在2029年凭借Kisunla及后续药物remternetug实现反超 [15] - 诺和诺德的semaglutide和罗氏的troninemab等新机制药物可能分割市场 压缩第一代抗体的市场份额 [11][15] - 欧盟批准将APOE-ε4纯合子患者排除在外 限制了Leqembi的短期应用范围 [4] 行业挑战与调整 - 自2024年6月以来 后期临床试验失败导致销售预测下调54% 2025-2030年风险调整后预期缩水70亿美元 [8] - 约半数医生质疑Leqembi疗效 70%符合条件患者拒绝用药 安全性担忧和获取障碍持续拖累应用 [11][13] - 渤健对Leqembi依赖度高 该药物2030年收入预计占公司总收入10% 而礼来的阿尔茨海默药物收入占比较小 [13][15]

Key Takeaways BIIB's Q2 results may reflect weaker MS drug sales but growth from newer products.Leqembi and Zurzuvae revenues are likely to have risen in the second quarter.Skyclarys faced mixed dynamics across U.S. and global marketsBiogen (BIIB) will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $2.32 billion and $3.95 per sha ...